Better Buy: Editas Medicine vs Sangamo Therapeutics
Gene editing as a sector has taken a backseat in terms of publicity and excitement now that the COVID-19 pandemic is on people's minds. However, its potential impact remains as significant as ever. With new treatments possibly able to cure genetic disorders previously considered incurable, there's a tremendous market for companies making breakthroughs in this innovative industry.
Both Editas Medicine (NASDAQ: EDIT) and Sangamo Therapeutics (NASDAQ: SGMO) have a number of potential treatments in the works right now. While both biotech stocks seem promising, if you had to pick between these two, which company is the better buy?
Image source: Getty Images.
Source Fool.com
